帕博利珠单抗(Pembrolizumab) - 药物靶点：PD-1_在研适应症：输卵管癌，非肌层浸润性膀胱肿瘤，卵巢上皮癌_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Lambrolizumab、Pembrolizumab (Genetical Recombination)、Pembrolizumab (genetical recombination) (JAN)

+ [12]

靶点

PD-1

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤免疫系统疾病感染+ [13]

在研适应症

输卵管癌非肌层浸润性膀胱肿瘤卵巢上皮癌+ [327]

非在研适应症

肢端雀斑恶性黑色素瘤急性髓性白血病NPM1突变急性髓系白血病+ [129]

原研机构

Merck & Co., Inc.

在研机构

Merck Sharp & Dohme BVMSD KK (Tokyo)

默沙东研发（中国）有限公司

+ [18]

非在研机构

Turnstone Biologics Corp.Merck Sharp & Dohme (Ireland) Ltd.

Eisai GmbH

+ [1]

权益机构

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

最高研发阶段批准上市

首次获批日期

美国 (2014-09-04),

黑色素瘤

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、优先药物（PRIME） (欧盟)、孤儿药 (日本)、孤儿药 (澳大利亚)、突破性疗法 (中国)、优先审评 (澳大利亚)、优先审评 (美国)、附条件批准 (中国)、优先审评 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 93660H

来源: *****

Sequence Code 93670L

来源: *****

关联

2,778

项与帕博利珠单抗相关的临床试验

NCT06093425

/ Not yet recruiting临床3期

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Pembrolizumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Gastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). In addition, the FDA has approved nivolumab, a PD-1 checkpoint inhibitor, in combination with chemotherapy as first line treatment for advanced or metastatic gastric/GEJ cancer. TST001 is a recombinant humanized monoclonal antibody against Claudin 18.2 (a tumor marker found in gastric/GEJ cancer. In this study, the combination therapy of chemotherapy or chemotherapy and pembrolizumab with and without TST001 could provide additional benefits to the management of these tumors.

开始日期2027-06-30

申办/合作机构

創勝醫藥集團有限公司

NCT04266730

/ Suspended临床1期

Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

开始日期2027-05-20

申办/合作机构

Lineberger Comprehensive Cancer Center

NCT07843550

/ Not yet recruiting临床1/2期

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.

开始日期2027-03-01

申办/合作机构

M.D. Anderson International España SA

100 项与帕博利珠单抗相关的临床结果

登录后查看更多信息

100 项与帕博利珠单抗相关的转化医学

登录后查看更多信息

100 项与帕博利珠单抗相关的专利（医药）

登录后查看更多信息

11,207

项与帕博利珠单抗相关的文献（医药）

2026-12-31·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

作者: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

2026-12-31·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States

Article

作者: Chafamo, Biruk ; Fernan, Catherine ; Muston, Dominic ; Qian, Feng ; Johnson, Geoffrey ; Tang, Yuexin ; Bensimon, Arielle G. ; Adkins, Douglas ; Zheng, Dandan ; Tzontcheva, Anjela ; Benjamin, Kimberly ; Uppaluri, Ravindra

AIMS:

In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-of-care [SOC] radiotherapy +/- cisplatin after surgery followed by pembrolizumab alone) significantly prolonged event-free survival vs. SOC alone, both in the intention-to-treat population and PD-L1 combined positive score (CPS) ≥1 subgroup. Perioperative pembrolizumab + SOC received Food and Drug Administration approval in June 2025 for resectable LA HNSCC expressing PD-L1 (CPS ≥ 1). The present study evaluated the cost-effectiveness of perioperative pembrolizumab + SOC versus SOC in this indication, from a US healthcare payer perspective.

MATERIALS AND METHODS:

A Markov cohort model with four states (event-free, local recurrence, incurable recurrence/progression, death) was developed to estimate lifetime costs, life years (LYs), and quality-adjusted LYs (QALYs) with 3% annual discounting. Transition probabilities were fitted to patient-level time-to-event data from KEYNOTE-689 through parametric multistate modelling. Costs of initial and subsequent treatment, adverse events, disease management, and terminal care were estimated in 2025$ based on trial results, drug labels, public databases, and literature. Utilities were derived through analyses of EQ-5D-5L data collected in KEYNOTE-689. Deterministic and probabilistic sensitivity analyses were performed.

RESULTS:

Compared to SOC, perioperative pembrolizumab + SOC increased total costs by $82,311 and provided gains of 1.47 QALYs and 1.77 LYs. Incremental cost-effectiveness ratios of perioperative pembrolizumab + SOC vs. SOC were $55,863/QALY and $46,406/LY. Higher initial treatment costs of perioperative pembrolizumab (incurred mainly in Year 1) were partially offset by lower recurrence-related costs. At the typical $150,000/QALY threshold, perioperative pembrolizumab + SOC was cost-effective in 96% of probabilistic simulations.

LIMITATIONS:

Survival extrapolations beyond the available trial period are subject to uncertainty.

CONCLUSIONS:

Perioperative pembrolizumab + SOC was found to be cost-effective versus SOC for the treatment of resectable LA HNSCC with CPS ≥ 1.

20,630

项与帕博利珠单抗相关的新闻（医药）

12 小时之前

·EndPoints

Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse merger

Antibody maker Paragon Therapeutics has formed another company, this time in the bustling cancer space of PD-1xVEGF, and it will go straight onto the public markets. The new biotech, named Crescent Biopharma, will take the place of GlycoMimetics on the Nasdaq, the companies said Tuesday morning. GlycoMimetics has failed multiple mid- and late-stage trials in recent months, including one for acute myeloid leukemia . The PD-1xVEGF space has become quite popular in recent months thanks to Keytruda-beating data from Summit Therapeutics and its Chinese partner Akeso. Former Seagen CEO David Epstein also joined a preclinical biotech, named Ottimo Pharma , on Monday that hopes to get bought out after Phase 1 data. BioNTech is also in the race. Crescent’s program, codenamed CR-001, will have initial proof of concept data in the second half of 2026, the company said. It also has two antibody-drug conjugates, another en-vogue area for oncology R&D. “This transaction and financing enable a potentially rapid development path for CR-001, and for the antibody-drug conjugate programs CR-002 and CR-003,” Crescent interim CEO Jonathan Violin said in a statement. Violin is also a venture partner at Fairmount, which is one of the investors supporting a concurrent $200 million financing for the merger, which will keep the R&D engine humming “through 2027,” the company said. Paragon has formed multiple autoimmune-focused biotechs over the past two years. Apogee went public via a traditional IPO, whereas other startups from its universe have landed on the public markets by way of reverse mergers, including Oruka and Spyre . In August, Paragon debuted another offshoot, named Jade Biosciences , with just a chief scientific officer and $80 million. Crescent’s shareholders will own almost all of the combined company, at 96.9%. The deal is anticipated to close in the second quarter of 2025.

IPO抗体药物偶联物

12 小时之前

·药研网

康方生物PD-1/VEGF双抗：海外又有2家初创锚定

10月28日，总部位于英国的Ottimo Pharma走出隐形模式。前Seagen公司的首席执行官David Epstein，在辉瑞以430亿美元收购Seagen后，现已加入一个新的生物技术公司Ottimo Pharma。 Ottimo Pharma还任命了前罗氏高管、现任BioMarin首席商务官James Sabry为副主席，以及勃林格殷格翰的资深人士Mehdi Shahidi为首席医学官。 Ottimo Pharma在过去三年中一直致力于Jankistomig的临床前开发，Jankistomig是一种双功能抗体，靶向PD1和VEGFR2，这两种受体参与帮助肿瘤生长和逃避免疫系统的分子途径。Ottimo Pharma一直在对该分子进行全面的临床前表征，并预计在2025年底提交IND。 10月29日，GlycoMimetics宣布已与Crescent Biopharma 公司达成收购协议。交易完成后，公司计划以Crescent Biopharma的名义运营，推进旨在治疗实体瘤的肿瘤疗法。Crescent Biopharma的主导项目CR-001是一款PD-1 x VEGF双特异性抗体。 Crescent是第五家利用 Paragon Therapeutics 发现和开发的资产上市的公司。Paragon此前孵化了Apogee Therapeutics、SPYRE THERAPEUTICS、ORUKA THERAPEUTICS和JADE BIOSCIENCES多个自免药物开发上市公司。 Crescent Biopharma 管线 Crescent Biopharma注与实体瘤药物的开发，目前管线中装入了三款药物: PD-1/VEGF双抗CR-001，另外两款为拓扑异构酶的ADC药物 CR-002 和 CR-003。 CR-001是一种四价PD-1 x VEGF双特异性抗体，其形式和药理学与康方生物的ivonescimab相匹配。与目前的市场领导者pembrolizumab相比，ivonescimib具有更优的疗效。该公司预计 CR-001 的 IND 将于 2025 年Q4或 2026 年Q1提交，患者的中期 1 期数据预计将于 2026 年下半年获得。除了 CR-001，Crescent还在开发 CR-002 和 CR-003，它们是使用拓扑异构酶抑制剂有效载荷针对未公开靶点的抗体-药物偶联物 (ADC)；与具有替代有效载荷的 ADC 相比，具有拓扑异构酶抑制剂有效载荷的 ADC 显示出更高的疗效和安全性。CR-002 是 Crescent 的首个 ADC 项目，旨在成为同类最佳项目，预计将于 2026 年启动第 1 阶段；Crescent计划在项目进入临床阶段时披露 CR-002 的目标。该交易预计将于 2025 年Q2完成。预计公司交割时的现金余额将为2027年的运营提供资金，包括推进公司的主要项目 CR-001，预计在 2026 年下半年通过对实体瘤患者的初步概念验证临床数据进行推进。 PD-1/VEGF潜力巨大。去年11月，BioNTech超10亿美元引进普米斯PD-L1/VEGF双抗，2024年9月，该双抗产品PM8002注射液的新药研究申请（IND）成功获得CDE的批准。目前，PM8002注射液已在国内针对TNBC、SCLC、非小细胞肺癌（NSCLC）等多个瘤种开展了多项临床试验研究，相关临床研究数据也陆续在重要的国际学术会议上发布，展示了其广阔的应用前景和潜在的巨大临床价值。超10亿美元，BioNTech引进普米斯PD-L1/VEGF双抗今年5月，康方生物宣布，全球首创PD-1/VEGF双抗依沃西单抗头对头对比Keytruda一线治疗PD-L1阳性NSCLC的三期临床HARMOIN-2（HARMONi-2或AK112-303）达到无进展生存期（PFS）的主要研究终点，显示强阳性结果。里程碑! 国产PD-1/VEGF双抗，头对头击败K药！ PD-1/VEGF双抗的大获成功再次引起了人们的关注。今年8月，宜明昂科将旗下PD-L1xVEGF双特异性抗体IMM2510大中华区以外的开发和商业化权利以5000万美元首付+20亿美元里程碑付款授予Instil Bio。由此可见，该领域的竞争激烈程度不言而喻。 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载/商务/投稿 | 联系微信15618157102（sum_Gmi）商务合作稿件征集点击了解详情往期回顾 1 8月 | 高达22家药企裁员 2 国产首款四价HPV疫苗拟纳入优先审评 3 3. 7亿美元!今年规模最大的生物医药融资诞生

抗体药物偶联物临床申请并购免疫疗法临床1期

12 小时之前

·PRNewswire

Crescent Biopharma Appoints Susan Moran, MD, MSCE, and Alexandra Balcom, MBA, CPA, to Board of Directors

New appointees, along with recently appointed Directors Peter Harwin and Interim CEO Jonathan Violin, PhD, provide a strong foundation for the company WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced it has appointed Susan Moran, MD, MSCA, former Chief Medical Officer of RayzeBio, Inc., and Alexandra Balcom, MBA, CPA, Chief Financial Officer of Nuvalent, Inc., to its Board of Directors. They join Jonathan Violin, PhD, Crescent's Interim Chief Executive Officer and Venture Partner at Fairmount, and Peter Harwin, Fairmount Co-founder, on the Board. "We are honored to have Dr. Moran and Ms. Balcom join the Board. Their appointments ensure we are well situated for rapid growth as we work to deliver potentially best-in-class therapies to patients with solid tumors," said Dr. Violin. "Dr. Moran brings deep experience in developing novel oncology therapeutics and Ms. Balcom offers a wealth of expertise in finance and operations, both at top-tier oncology companies. We are all extremely excited by the potential impact of Crescent's pipeline, led by CR-001, our tetravalent PD-1 x VEGF bispecific antibody. CR-001 was specifically designed to uniquely recapitulate the groundbreaking cooperative binding mechanism of action that recently demonstrated superiority to pembrolizumab in a large Phase 3 clinical trial." Dr. Moran brings to the Crescent Board more than 20 years of industry and academic experience. Most recently, she served as Chief Medical Officer for RayzeBio until its acquisition in 2024 by Bristol Myers Squibb. Dr. Moran currently serves on the Board of Directors of Tyra Biosciences, Inc., and BioAtla, Inc., both publicly traded clinical-stage biotechnology companies. She was previously Chief Medical Officer at QED Therapeutics and prior to that, led clinical development at Puma Biotechnology. Dr. Moran received her B.A. from the University of Virginia, her M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine, and her M.D. from Duke University. Ms. Balcom is currently the Chief Financial Officer at Nuvalent. Prior to joining Nuvalent, she served as Vice President of Finance at SQZ Biotechnologies, where she helped raise more than $200 million in private and public equity financing, including the company's 2020 initial public offering. Previously, Ms. Balcom served as Corporate Controller at Agios Pharmaceuticals, supporting more than $700 million in equity financing. She earned her B.B.A. in Finance from the University of Massachusetts, Amherst, and her M.B.A. from Boston College. She is also a Certified Public Accountant in Massachusetts. The company is on track to close its previously announced acquisition by GlycoMimetics in the second quarter of 2025, after which the combined company will advance Crescent's pipeline and be renamed Crescent Biopharma. Having recently secured $200 million in financing through a private placement from a leading syndicate of biotechnology investors, Crescent is funded through 2027, including through initial clinical data for CR-001, which is expected in the second half of 2026. The company is also advancing CR-002 and CR-003, antibody-drug conjugates with topoisomerase inhibitor payloads for undisclosed targets. About CR-001 CR-001 is a tetravalent PD-1 x VEGF bispecific antibody in development for treating solid tumors. It was designed to recapitulate the targeting, geometry, and cooperativity of ivonescimab, another tetravalent PD-1 x VEGF bispecific antibody that demonstrated efficacy superior to market-leading pembrolizumab in a large Phase 3 clinical trial. CR-001 was specifically designed to avoid mechanistic risks that could perturb the balance of efficacy and safety that define this new class of immunotherapy. About Crescent Biopharma Crescent Biopharma is a biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors. The company's pipeline of three programs harnesses proven biology to accelerate the path to market for potentially best in class therapeutics. The company's lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody; it is also advancing CR-002 and CR-003, antibody-drug conjugates with topoisomerase inhibitor payloads for undisclosed targets. For more information, visit . Media Contact Deerfield Group Lia Dangelico 540-303-0180 [email protected] Investor Contact: Argot Partners Dawn Schottlandt 212-600-1902 [email protected] SOURCE Crescent Biopharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更临床3期并购IPO

100 项与帕博利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10574	帕博利珠单抗	L01FF02	DB09037

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
输卵管癌	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
非肌层浸润性膀胱肿瘤	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
浸润性膀胱癌	欧盟	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	冰岛	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	列支敦士登	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	挪威	Merck Sharp & Dohme BV	2026-07-01
铂耐药性输卵管癌	中国	Merck Sharp & Dohme LLC	2026-06-23
铂类耐药性原发性腹膜癌	欧盟	Merck Sharp & Dohme BV	2026-04-22
铂类耐药性原发性腹膜癌	列支敦士登	Merck Sharp & Dohme BV	2026-04-22
铂耐药上皮性卵巢癌	欧盟	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	冰岛	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	列支敦士登	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	挪威	Merck & Co., Inc.	2026-04-02
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme Corp.	2026-02-10
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme LLC	2026-02-10
肿瘤	美国	Merck Sharp & Dohme Corp.	2026-02-10
肿瘤	美国	Merck Sharp & Dohme LLC	2026-02-10
卵巢癌	美国	Merck Sharp & Dohme LLC	2026-02-10
卵巢癌	美国	Merck Sharp & Dohme Corp.	2026-02-10
肌层浸润性膀胱癌	美国	Merck Sharp & Dohme Corp.	2025-11-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期非鳞状非小细胞肺癌	申请上市	中国	默沙东研发（中国）有限公司	2026-10-27
局部晚期非鳞状非小细胞肺癌	申请上市	中国	Merck Sharp & Dohme Corp.	2026-10-27
复发性铂耐药性卵巢癌	申请上市	美国	Merck & Co., Inc.	2025-10-20
小肠癌	申请上市	欧盟	Merck Sharp & Dohme Corp.	2022-03-25
非小细胞肺癌Ⅰ期	临床3期	美国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	日本	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	澳大利亚	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	巴西	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	加拿大	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	智利	Merck Sharp & Dohme LLC	2026-05-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02617849 (Pubmed \| Oncoimmunology)	临床2期	黑色素瘤	30	Pembrolizumab and Carboplatin/ Paclitaxel	觸壓製積觸壓鹹襯餘鏇(積憲窪膚淵繭獵鏇艱鹹) = 鹽鏇淵餘築壓齋鑰壓願艱餘餘齋構廠壓衊顧積 (製顧廠積淵鹹鑰鏇鹹繭 ) 更多	不佳	2026-12-31
ACR2026	N/A	肾细胞癌	27,394	ICI (RA)	願醖糧醖壓鑰願夢糧遞(製選選餘蓋簾製淵壓獵) = 衊構憲鬱蓋顧鑰壓顧遞窪願選淵鹹襯觸遞壓鹹 (築衊醖蓋襯醖窪獵淵範 ) 更多	积极	2026-11-06
				ICI (non-RA)	願醖糧醖壓鑰願夢糧遞(製選選餘蓋簾製淵壓獵) = 壓襯願網鑰築夢選網壓窪願選淵鹹襯觸遞壓鹹 (築衊醖蓋襯醖窪獵淵範 ) 更多
AASLD2026	临床2/3期	晚期胆道癌一线	3,000	Durvalumab + Gemcitabine + Cisplatin	窪願製窪顧襯鹹鹽鑰蓋(淵齋構憲襯齋蓋製蓋齋): HR = 0.74 (95.0% CI, 0.63 ~ 0.87)	积极	2026-11-05
				Pembrolizumab + Gemcitabine + Cisplatin
AASLD2026	N/A	不可切除的肝内胆管癌 TP53 mutations	41	gemcitabine, cisplatin, and durvalumab (GCD) or gemcitabine, cisplatin, and pembrolizumab (GCP)	網憲簾鏇鬱糧觸遞鬱鏇(憲蓋壓願選顧範廠簾製) = 選鬱範醖糧襯築顧艱顧顧遞網糧積選遞築鏇膚 (鏇遞顧鹽窪積獵鏇鑰簾, 4.4 ~ 10.7) 更多	积极	2026-11-05
				gemcitabine, cisplatin, and durvalumab (GCD) or gemcitabine, cisplatin, and pembrolizumab (GCP) (TP53 wild-type ICC)	網憲簾鏇鬱糧觸遞鬱鏇(積構顧鹽範範齋淵觸鏇) = 憲獵膚醖艱壓構鹹淵糧襯鏇築憲網獵願構膚選 (顧襯壓鹹齋鹹壓夢憲願, 4.4 ~ 10.7) 更多
NCT04753879 (CTgov)	临床2期	转移性胰腺癌 \| 转移性胰腺导管腺癌	36	Olaparib+Nab-paclitaxel+Gemcitabine+Cisplatin+Pembrolizumab+Irinotecan+capecitabine	簾廠淵醖窪壓餘齋簾糧 = 廠築獵齋醖構網願範夢範觸築網積膚築鹽餘夢 (鹹鬱糧顧鏇壓鏇壓築齋, 網襯製廠願餘願簾蓋齋 ~ 蓋鑰範顧鬱夢膚糧願餘) 更多	-	2026-11-04
NCT03598608 (MK-4280-003, Pubmed \| Blood Neoplasia)	临床1/2期	难治性经典霍奇金淋巴瘤 PD-1	34	Favezelimab 800 mg plus Pembrolizumab 200 mg	廠襯鏇壓選獵夢艱築鹹(鏇觸夢觸窪廠蓋衊繭鏇) = 1 of 21 participants experienced a dose-limiting toxicity (grade 4 autoimmune hepatitis) 製憲觸築廠衊鏇壓衊獵 (選壓簾積顧獵糧製膚獵 ) 更多	积极	2026-11-01
NCT04165083 (KEYMAKER-U01 substudy 01B \| KEYMAKER-U01B \| MK-3475-01B, CTgov)	临床2期	PD-L1阳性非小细胞肺癌	100	MK-4830+Pembrolizumab (MK-4830 + Pembrolizumab)	製艱艱積願製廠顧製觸 = 膚積衊構鑰範鑰齋憲顧製鹹夢鹽簾夢壓遞壓觸 (壓糧觸積簾壓網憲鑰憲, 鏇醖觸獵淵選艱範觸願 ~ 鬱獵簾築遞簾衊鹽鬱鬱) 更多	-	2026-10-29
				MK-0482+Pembrolizumab (MK-0482 + Pembrolizumab)	製艱艱積願製廠顧製觸 = 夢繭鏇積夢壓顧鏇蓋繭製鹹夢鹽簾夢壓遞壓觸 (壓糧觸積簾壓網憲鑰憲, 糧壓鏇餘鹽糧憲餘鹽製 ~ 餘衊蓋顧鬱遞願網壓鏇) 更多
NCT04643379 (CTgov)	临床2期	转移性头颈部鳞状细胞癌 \| 复发性头颈部鳞状细胞癌	30	Peripheral blood draw+Olaparib+Carboplatin+Pembrolizumab	窪艱壓觸襯膚範築淵顧 = 獵鹹蓋壓鑰窪鹹膚壓網遞淵窪鬱選醖襯醖夢築 (鹽淵衊製鬱蓋築繭積淵, 窪築憲衊蓋築顧壓遞膚 ~ 襯範願鏇網選鬱廠範顧) 更多	-	2026-10-27
NCT06780111 (KEYMAKER-U06, ESMO2026)	临床1/2期	晚期食管鳞状细胞癌一线	50	Sacituzumab tirumotecan + pembrolizumab + chemotherapy	鹹願淵鹹艱鑰築製獵觸(獵製壓廠範鏇鏇鹽觸醖) = 簾選觸蓋鏇製膚艱製範壓鏇廠網齋觸窪齋膚願 (範鑰淵醖糧鹽憲範網窪 ) 更多	积极	2026-10-23
NCT05642780 (2870-002/SKB264-II-06, ESMO2026)	临床2期	转移性尿路上皮癌 TROP2 \| PD-L1	40	Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro)	繭構餘網簾鹹顧膚積獵(簾醖鏇積齋艱壓廠鬱醖) = 餘顧夢築淵壓網夢鑰願遞衊膚鹽願繭醖鏇餘壓 (觸艱鏇蓋積衊積製餘壓, 51 ~ 81) 更多	积极	2026-10-23
				Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro)	繭構餘網簾鹹顧膚積獵(簾醖鏇積齋艱壓廠鬱醖) = 製顧鬱網窪襯壓壓遞築遞衊膚鹽願繭醖鏇餘壓 (觸艱鏇蓋積衊積製餘壓, 47 ~ 90)